As per our new research report, “Cancer Generics Market Analysis”, the pharma companies around the world are now resorting to the generic versions of top branded cancer drugs to support the demand without the price issues. Earlier, the companies were not so inclined towards generic oncology drugs due to low profitability. But the rising concerns over healthcare expenditure in the developed nations have forced the governments to support the uptake of generic versions.
Our study indicates that companies including Actavis, Endo Pharmaceuticals Holdings Inc., Nichi-Iko Pharmaceutical Co, Natco Pharma Ltd, Akrihin, and Astrazeneca have recently forayed investments to widen up their generics cancer drug pipeline.
We have conducted thorough research and prudent analysis of Global Generics Cancer drug market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that the industry witnessed a number of product launches and mergers & acquisitions in the past few years. The main focus of the companies has been to introduce effective and quality products in the market so that it gains a worldwide acceptance. With new markets and new products for generics manufacturers within the cancer market, it is anticipated that a harsh environment for companies focusing on novel cancer treatments is about to come. However, within the cancer market, there remains a high level of unmet need, and novel products demonstrating improved clinical attributes to any degree would be expected to capture market share from older generic drugs.
“Cancer Generics Market Analysis” provides extensive information and rational analysis of the global cancer generics drugs market. It has thoroughly examined current market drivers, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in the coming years. The report also provides an insight into different marketed products along with pipeline analysis to present an overview of the developments taking place in the global cancer generics drugs industry. Further, a review of product introductions/innovations and recent industry activities has also been covered in this report to help clients formulate appropriate strategies for the expansion of business in untapped markets.
|
